Literature DB >> 32820487

The Anticoagulant and Nonanticoagulant Properties of Heparin.

Danielle M H Beurskens1, Joram P Huckriede1, Roy Schrijver1, H Coenraad Hemker2, Chris P Reutelingsperger1, Gerry A F Nicolaes1.   

Abstract

Heparins represent one of the most frequently used pharmacotherapeutics. Discovered around 1926, routine clinical anticoagulant use of heparin was initiated only after the publication of several seminal papers in the early 1970s by the group of Kakkar. It was shown that heparin prevents venous thromboembolism and mortality from pulmonary embolism in patients after surgery. With the subsequent development of low-molecular-weight heparins and synthetic heparin derivatives, a family of related drugs was created that continues to prove its clinical value in thromboprophylaxis and in prevention of clotting in extracorporeal devices. Fundamental and applied research has revealed a complex pharmacodynamic profile of heparins that goes beyond its anticoagulant use. Recognition of the complex multifaceted beneficial effects of heparin underscores its therapeutic potential in various clinical situations. In this review we focus on the anticoagulant and nonanticoagulant activities of heparin and, where possible, discuss the underlying molecular mechanisms that explain the diversity of heparin's biological actions. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32820487     DOI: 10.1055/s-0040-1715460

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

Review 1.  Circulating Histones in Sepsis: Potential Outcome Predictors and Therapeutic Targets.

Authors:  Yupei Li; Dingyuan Wan; Xinyao Luo; Tao Song; Yiran Wang; Qiao Yu; Luojia Jiang; Ruoxi Liao; Weifeng Zhao; Baihai Su
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

Review 2.  Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Stefanie Reis; Maria Popp; Benedikt Schmid; Miriam Stegemann; Maria-Inti Metzendorf; Peter Kranke; Patrick Meybohm; Stephanie Weibel
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

Review 3.  Heparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules.

Authors:  Nipa Banik; Seong-Bin Yang; Tae-Bong Kang; Ji-Hong Lim; Jooho Park
Journal:  Int J Mol Sci       Date:  2021-09-29       Impact factor: 5.923

4.  POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes.

Authors:  Tobias Tritschler; Grégoire Le Gal; Shari Brosnahan; Marc Carrier
Journal:  Chest       Date:  2022-03-15       Impact factor: 10.262

Review 5.  Heparan Sulfate and Sialic Acid in Viral Attachment: Two Sides of the Same Coin?

Authors:  Ivan Emmanuel Ramos-Martínez; Edgar Ramos-Martínez; René Álvaro Segura-Velázquez; Manuel Saavedra-Montañez; Jacquelynne Brenda Cervantes-Torres; Marco Cerbón; Dulce Papy-Garcia; Edgar Zenteno; José Ivan Sánchez-Betancourt
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

Review 6.  Management of Anticoagulation during Extracorporeal Membrane Oxygenation in Children.

Authors:  Madhuradhar Chegondi; Niranjan Vijayakumar; Balagangadhar R Totapally
Journal:  Pediatr Rep       Date:  2022-07-11

7.  Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: a retrospective analysis from the MIMIC-IV database.

Authors:  Zhi-Ye Zou; Jia-Jia Huang; Ying-Yi Luan; Zhen-Jia Yang; Zhi-Peng Zhou; Jing-Jing Zhang; Yong-Ming Yao; Ming Wu
Journal:  Burns Trauma       Date:  2022-09-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.